Lundbeck hikes annual forecasts as migraine drug powers earnings beat

1

Nov 10 (Reuters) – Danish drugmaker Lundbeck raised its full-year sales and profit forecasts on Tuesday after third-quarter earnings beat expectations, citing strong demand for its migraine treatment

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)